amuvatinib + platinum + etoposide

Amuvatinib + platinum + etoposide is an **investigational combination therapy** evaluated primarily in the treatment of platinum-refractory small cell lung cancer (SCLC)[1][3][5][7][9]. The regimen combines **amuvatinib (MP-470)**, an oral multi-targeted tyrosine kinase inhibitor with activity against c-Kit, platelet-derived growth factor receptor alpha (PDGFRα), FLT3, c-MET, and c-RET, with a standard platinum agent (such as cisplatin or carboplatin) and **etoposide** (a DNA topoisomerase II inhibitor). Amuvatinib inhibits DNA repair by downregulating **RAD51**, impairing homologous recombination repair of double-stranded DNA breaks, and is synergistic with DNA-damaging agents such as platinum drugs and etoposide. The combination was developed based on preclinical evidence of potentiated anti-tumor activity—especially in models with high c-Kit expression. In clinical trials, this combination was studied for efficacy, survival, and tolerability, but did not show sufficient benefit to warrant further unselected development in SCLC.

Other names

amuvatinib + platinum-etoposideamuvatinib + EPamuvatinib + platinum-based chemotherapy + etoposide